HIV-1 in strand transfer chelating inhibitors: A focus on metal binding

Molecular Pharmaceutics

Volumn 8, Issue 2, 2011, Pages 507-519

  Bacchi, Alessia ^a   Carcelli, Mauro ^a   Compari, Carlotta ^a   Fisicaro, Emilia ^a   Pala, Nicolino ^b   Rispoli, Gabriele ^a   Rogolino, Dominga ^a   Sanchez, Tino W ^c   Sechi, Mario ^b   Neamati, Nouri ^c  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

coordinating pharmacophores; HIV 1 integrase; metal complexes; S 1360; strand transfer selective inhibitors

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; 2 HYDROXY 4 OXO 4 (3,5 BENZYLOXY)PHENYLBUT 2 ENOIC ACID; INTEGRASE; INTEGRASE INHIBITOR; L 708906; MAGNESIUM DERIVATIVE; MAGNESIUM ION; MANGANESE; MANGANESE DERIVATIVE; METAL COMPLEX; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CHELATION; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG MECHANISM; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS 1; METAL BINDING; PH; PRIORITY JOURNAL; SOLID STATE; X RAY CRYSTALLOGRAPHY; X RAY DIFFRACTION;

CHELATING AGENTS; CRYSTALLOGRAPHY, X-RAY; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HUMANS; MAGNESIUM; MANGANESE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; ORGANOMETALLIC COMPOUNDS; STEREOISOMERISM;

EID: 79953835779     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp100343x     Document Type: Article

References (63)

1. Pommier, Y.; Johnson, A. A.; Marchand, C. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discovery 2005, 4, 236-248.
2. Neamati, N.; Marchand, C.; Pommier, Y. HIV-1 integrase inhibitors: past, present, and future. Adv. Pharmacol. 2000, 49, 147-165.
3. D'Angelo, J.; Mouscadet, J. F.; Desmaele, D.; Zouhiri, F.; Leh, H. HIV-1 integrase: the next target for AIDS therapy?. Pathol. Biol. 2001, 49, 237-246.
4. Neamati, N. Structure-based HIV-1 inhibitor design: a future perspective. Expert Opin. Invest. Drugs 2001, 10, 281-296.
5. Anthony, N. J. HIV-1 integrase: a target for new AIDS chemotherapeutics. Curr. Top. Med. Chem. 2004, 4, 979-990.
6. Nair, V.; Chi, G. HIV integrase inhibitors as therapeutic agents in AIDS. Rev. Med. Virol. 2007, 17, 277-295.
7. Dayam, R.; Al-Mawsawi, L. Q.; Neamati, N. HIV-1 Integrase Inhibitors: An Emerging Clinical Reality. Drugs R&D 2007, 8, 155-168.
8. MK-0518 meeting transcript. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research; Antiviral Drugs Advisory Committee; 2007 September 5. Available from www.fda.gov/ohrms/ dockets/ac/cder07.htm#AntiviralDrugs.
9. Al-Mawsawi, L. Q.; Al-Safi, R. I.; Neamati, N. Expert. Opin. Emerging Drugs 2008, 13, 213-225.
10. Kulkosky, J.; Jones, K. S.; Katz, R. A.; Mack, J. P.; Skalka, A. M. Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases. Mol. Cell. Biol. 1992, 12, 2331-2338.
11. Hazuda, D. J.; Felock, P.; Witmer, M.; Wolfe, A.; Stillmock, K.; Grobler, J. A.; Espeseth, A.; Gabryelski, L.; Schleif, W.; Blau, C.; Miller, M. D. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000, 287, 646-50. (Pubitemid 30070911)
12. Goldgur, Y.; Craigie, R.; Cohen, G. H.; Fujiwara, T.; Yoshinaga, T.; Fujishita, T.; Sugimoto, H.; Endo, T.; Murai, H.; Davies, D. R. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 13040-13043.
13. Pais, G. C. G.; Burke, T. R. Novel aryl diketo-containing inhibitors of HIV-1 integrase. Drugs Future 2002, 27, 1101-1111.
14. Egbertson, M. S. HIV integrase inhibitors: from diketoacids to heterocyclic templates: a history of HIV integrase medicinal chemistry at Merck West Point and Merck Rome (IRBM). Curr. Top. Med. Chem. 2007, 7, 1251-1272.
15. Wang, Y.; Serradell, N.; Bolos, J.; Rosa, E. MK-0518, HIV integrase inhibitor. Drugs Future 2007, 32, 118-122.
16. Rowley, M. The Discovery of Raltegravir, An Integrase Inhibitor for the Treatment of HIV Infection. Prog. Med. Chem. 2008, 46, 1-28.
17. Summa, V.; Petrocchi, A.; Bonelli, F.; Crescenzi, B.; Donghi, M.; Ferrara, M.; Fiore, F.; Gardelli, C.; Gonzalez, P. O.; Hazuda, D. J.; Jones, P.; Kinzel, O.; Laufer, R.; Monteagudo, E.; Muraglia, E.; Nizi, E.; Orvieto, F.; Pace, P.; Pescatore, G.; Scarpelli, R.; Stillmock, K.; Witmer, M. V.; Rowley, M. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J. Med. Chem. 2008, 51, 5843-5855.
18. Sato,M.;Motomura, T.; H. Aramaki, H.;Matsuda, T.; Yamashita, M.; Ito, Y.; Kawakami, H.; Matsuzaki, Y.; Watanabe, W.; Yamataka, K.; Ikeda, S.; Kodama, E.; Matsuoka, M.; Shinkai, H. Novel HIV-1 Integrase Inhibitors Derived from Quinolone Antibiotics. J. Med. Chem. 2006, 49, 1506-1508.
19. Dayam, R.; Al-Mawsawi, L. Q.; Zawahir, Z.; Witvrouw, M.; Debyser, Z.; Neamati, N. Quinolone 3-Carboxylic Acid Pharmacophore: Design of Second Generation HIV-1 Integrase Inhibitors. J. Med. Chem. 2008, 51, 1136-1144.
20. Di Santo, R.; Costi, R.; Roux, A.; Artico, M.; Lavecchia, A.; Marinelli, L.; Novellino, E.; Palmisano, L.; Andreotti, M.; Amici, R.; Galluzzo, C. M.; Nencioni, L.; Palamara, A. T.; Pommier, Y.; Marchand, C. Novel Bifunctional Quinolonyl Diketo Acid Derivatives as HIV-1 Integrase Inhibitors: Design, Synthesis, Biological Activities, and Mechanism of Action. J. Med. Chem. 2006, 49, 1939-1945.
21. Pasquini, S.; Mugnaini, C.; Tintori, C.; Botta, M.; Trejos, A.; Arvela, R. K.; Larhed, M.; Witvrouw, M.; Michiels, M.; Christ, F.; Debyser, Z.; Corelli, F. Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 1. Synthesis and Structure-Activity Relationship of a Class of Human Immunodeficiency Virus type 1 Integrase Inhibitors. J. Med. Chem. 2008, 51, 5125-5129.
22. Hare, S.; Gupta, S. S.; Valkov, E.; Engelman, A.; Cherepanov, P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010, 464, 232-236.
23. Hazuda, D. J.; Anthony, N. J.; Gomez, R. P.; Jolly, S. M.; Wai, J. S.; Zhuang, L.; Fisher, T. E.; Embrey, M.; Guare, J. P., Jr.; Egbertson, M. S.; Vacca, J. P.; Huff, J. R.; Felock, P. J.; Witmer, M. V.; Stillmock, K. A.; Danovich, R.; Grobler, J.; Miller, M. D.; Espeseth, A. S.; Jin, L.; Chen, I.-W.; Lin, J. H.; Kassahun, K.; Ellis, J. D.; Wong, B. K.; Xu, W.; Pearson, P. G.; Schleif, W. A.; Cortese, R.; Emini, E.; Summa, V.; Holloway, M. K.; Young, S. D. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 11233-11238.
24. Dayam, R.; Neamati, N. Active site binding modes of the beta-diketoacids: a multi-active site approach in HIV-1 integrase inhibitor design. Bioorg. Med. Chem. 2004, 12, 6371-6381.
25. Pais, G. C. G.; Zhang, X.; Marchand, C.; Neamati, N.; Cowansage, K.; Svarovskaia, E. S.; Pathak, V. K.; Tang, Y.; Nicklaus, M.; Pommier, Y.; Burke, T. R., Jr. Structure Activity of 3-Aryl-1,3-diketocontaining compounds as HIV-1 Integrase inhibitors. J. Med. Chem. 2002, 45, 3184-3194.
26. Zhao, X. Z.;Maddali, K.; Vu, B. C.;Marchand, C.; Hughes, S. H.; Pommier, Y.; Burke, T. R., Jr. Examination of halogen substituent effects on HIV-1 integrase inhibitors derived from 2,3-dihydro-6,7-dihydroxy-1H-isoindol- 1-ones and 4,5-dihydroxy-1H-isoindole-1,3(2H)-diones. Bioorg. Med. Chem. Lett. 2009, 19, 2714-2717.
27. Kirschberg, T.; Parrish, J. Metal chelators as antiviral agents. Curr. Opin. Drug Discovery 2007, 10, 460-472.
28. Shaw-Reid, C. A.; Munshi, V.; Graham, P.; Wolfe, A.; Witmer, M.; Danzeisen, R.; Olsen, D. B.; Carroll, S. S.; Embrey, M.; Wai, J. S.; Miller, M. D.; Cole, J. L.; Hazuda, D. J. Inhibition of HIV-1 Ribonuclease H by a Novel Diketo Acid, 4-[5-(Benzoylamino)thien-2-yl]-2,4-dioxobutanoic Acid. J. Biol. Chem. 2003, 278, 2777-2780. (Pubitemid 36801178)
29. Tramontano, E.; Esposito, F.; Badas, R.; Di Santo, R.; Costi, R.; La Colla, P. 6-[1-(4-Fluorophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in vitro. Antiviral Res. 2005, 65, 117-124.
30. Billamboz, M.; Bailly, F.; Barreca, M. L.; De Luca, L.; Mouscadet, J.-F.; Calmels, C.; Andreola, M.-L.; Witvrouw, M.; Christ, F.; Debyser, Z.; Cotelle, P. Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain. J. Med. Chem. 2008, 51, 7717-7730.
31. Wang, Z.; Tang, J.; Salomon, C. E.; Dreis, C. D.; Vince, R. Pharmacophore and structure-activity relationships of integrase inhibition within a dual inhibitor scaffold of HIV reverse transcriptase and Integrase. Bioorg. Med. Chem. 2010, 18, 4202-4211.
32. Kijama, R.; Kawasuji, T. PCT Int. Appl. 2001, WO-01/95905.
33. Kawasuji, T.; Fuji, M.; Yoshinaga, T.; Sato, A.; Fujiwara, T.; Kiyama, R. A platform for designing HIV integrase inhibitors. Part 2: A two-metal binding model as a potential mechanism of HIV integrase inhibitors. Bioorg. Med. Chem. 2006, 14, 8420-8429.
34. Kawasuji, T.; Fuji, M.; Yoshinaga, T.; Sato, A.; Fujiwara, T.; Kiyama, R. 3-Hydroxy-1,5-dihydro-pyrrol-2-one derivatives as advanced inhibitors of HIV integrase. Bioorg. Med. Chem. 2007, 15, 5487-5492.
35. Grobler, J. A.; Stillmock, K.; Hu, B.; Witmer, M.; Felock, P.; Espeseth, A. S.; Wolfe, A.; Egbertson, M.; Bourgeois, M.; Melamed, J.; Wai, J. S.; Young, S.; Vacca, J.; Hazuda, D. J. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 6661-6666.
36. Maurin, C.; Bailly, F.; Buisine, E.; Vezin, H.; Mbemba, G.; Mouscadet, J. F.; Cotelle, P. Spectroscopic Studies of Diketoacids-Metal Interactions. A Probing Tool for the Pharmacophoric Intermetallic Distance in the HIV-1 Integrase Active Site. J. Med. Chem. 2004, 47, 5583-5596.
37. Sechi, M.; Bacchi, A.; Carcelli, M.; Compari, C.; Duce, E.; Fisicaro, E.; Rogolino, D.; Gates, P.; Derudas, M.; Al-Mawsawi, L. Q.; Neamati, N. From Ligand to Complexes: Inhibition of Human Immunodeficiency Virus Type 1 Integrase by β-Diketo Acid Metal Complexes. J. Med. Chem. 2006, 49, 4248-4260.
38. Bacchi, A.; Biemmi, M.; Carcelli, M.; Carta, F.; Compari, C.; Fisicaro, E.; Rogolino, D.; Sechi, M.; Sippel, M.; Sotriffer, C.; Sanchez, T. W.; Neamati, N. From Ligand to Complexes. Part 2. Remarks on Human Immunodeficiency Virus Type 1 Integrase inhibition by β-Diketo Acid Metal Complexes. J. Med. Chem. 2008, 51, 7253-7264.
39. Courcot, B.; Firley, D.; Fraisse, B.; Becker, P.; Gillet, J. M.; Pattison, P.; Chernyshov, D.; Sghaier, M.; Zouhiri, F.; Desmaele, D.; d'Angelo, J.; Bonhomme, F.; Geiger, S.; Ghermani, N. E. Crystal and electronic structures of magnesium(II), copper(II), and mixed magnesium(II)-copper(II) complexes of the quinoline half of styrylquinoline-type HIV-1 integrase inhibitors. J. Phys. Chem. B 2007, 111, 6042-6050.
40. Drevensek, P.; Košmrlj, J.; Giester, G.; Skauge, T.; Sletten, E.; Sepčić, K; Turel, I. X-Ray crystallographic, NMR and antimicrobial activity studiesof magnesium complexes of fluoroquinolones - racemic ofloxacin and its S-form, levofloxacin. J. Inorg. Biochem. 2006, 100, 1755-1763.
41. Turel, I.; Živec, P.; Pevec, A.; Tempelaar, S; Psomas, G. Compounds of antibacterial agent Ciprofloxacin and Magnesium - Crystal structures and molecular modeling calculations. Eur. J. Inorg. Chem. 2008, 3718-3727.
42. Chen, I. J.; Neamati, N.; MacKerell, A. D., Jr. Structure-based inhibitor design targeting HIV-1 integrase. Curr. Drug Targets: Infect. Disord. 2002, 2, 217-234.
43. Maurin, C.; Bailly, F.; Cotelle, P. Structure-activity relationship of HIV-1 integrase inhibitor-enzyme-ligand interaction. Curr. Med. Chem. 2003, 10, 1795-1810.
44. Sato, M.; Motomura, T.; Aramaki, H.; Matsuda, T.; Yamashita, M.; Ito, Y.; Matsuzaki, Y.; Yamataka, K.; Ikeda, S.; Shinkai, H. Quinolone carboxylic acids as a novel monoketo acid class of Human Immunodeficiency Virus Type1 Integrase inhibitors. J. Med. Chem. 2009, 52, 4869-4882.
45. DeJesus, E.; Berger, D.; Markowitz, M.; Cohen, C.; Hawkins, T.; Ruane, P.; Elion, R.; Farthing, C.; Zhong, L.; Chen, A. K.; McColl, D.; Kearney, B. P. Antiviral Activity, Pharmacokinetics, and Dose Response of the HIV-1 Integrase Inhibitor GS-9137 (JTK-303) in Treatment-Naive and Treatment-Experienced Patients. J. Acquired Immune Defic. Syndr. 2006, 43, 1-5.
46. Johnson, A. A.; Marchand, C.; Pommier, Y. HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trial. Curr. Top. Med. Chem. 2004, 4, 671-686.
47. Maurin, C.; Bailly, F.; Cotelle, P. Improved preparation and structural investigation of 4-aryl-4-oxo-2-hydroxy-2-butenoic acids and methyl esters. Tetrahedron 2004, 60, 6479-6486. (Pubitemid 39090244)
48. Sechi, M.; Carta, F.; Sannia, L.; Dallocchio, R.; Dess, A.; Neamati, N. Design, synthesis, molecular modeling, and anti-HIV-1 integrase activity of a series of photoactivatable diketo acid-containing inhibitors as affinity probes. Antiviral Res. 2009, 81, 267-276.
49. Gatehouse, B. M.; O'Connor, M. J. The crystal and molecular structure of racemic [bis(ethylenediamine)acetylpyruvato]cobalt(III) iodide monohydrate. Acta Crystallogr. 1976, B32, 3145-3148.
50. Kawai, H.; Kitano, Y.; Mutoh, M.; Hata, G. Synthesis, structure and antitumor activity of a new water-soluble platinum complex, (1R, 2R-cyclohexanediamine-N,N0)[2-hydroxy-4-oxo-2-pentenoato(2-)-O2]-platinum(II). Chem. Pharm. Bull. 1993, 41, 357-361.
51. Barreca, M. L.; Iraci, N.; De Luca, L.; Chimirri, A. Induced-Fit docking approach provides insight into the bindingmode and mechanism of action of HIV-1 Integrase inhibitors. ChemMedChem 2009, 4, 1446-1456.
52. Liao, C.; Nicklaus, M. C. Tautomerism and Magnesium chelation of HIV-1 Integrase inhibitors: a theoretical study. ChemMedChem 2010, 5, 1053-1066.
53. Cremer, D.; Pople, J. A. General definition of ring puckering coordinates. J. Am. Chem. Soc. 1975, 97, 1354.
54. Al-Mawsawi, L. Q.; Sechi, M.; Neamati, N. Single amino acid substitution in HIV-1 integrase catalytic core causes a dramatic shift in inhibitor selectivity. FEBS Lett. 2007, 581, 1151-1156. (Pubitemid 46385937)
55. Marchand, C.; Johnson, A. A.; Karki, R. G.; Pais, G. C. G.; Zhang, X.; Cowansage, K.; Patel, T. A.; Nicklaus, M. C.; Burke, T. R., Jr.; Pommier, Y. Metal-Dependent Inhibition of HIV-1 Integrase by β-Diketo Acids and Resistance of the Soluble Double-Mutant (F185K/C280S). Mol. Pharmacol. 2003, 64, 600-609. (Pubitemid 37048563)
56. SAINT: SAX, Area Detector Integration; Siemens Analytical instruments Inc.: Madison, Wisconsin, USA.
57. SADABS: Area-Detector Absorption Correction; Siemens Industrial Automation, Inc.: Madison, Wisconsin, USA, 1996.
58. Altomare, A.; Cascarano, G.; Giacovazzo, C.; Guagliardi, A.; Burla, M. C.; Polidori, G.; Camalli, M. SIR92 - a program for automatic solution of crystal structures by direct methods. J. Appl. Crystallogr. 1994, 27, 435.
59. SHELXL97: Sheldrick, G. M. SHELXL97. Program for structure refinement; University of Göttingen: Göttingen, Germany, 1997.
60. Allen, F. H.; Kennard, O.; Taylor, R. Systematic analysis of structural data as a research technique in organic chemistry. Acc. Chem. Res. 1983, 16, 146-153.
61. Fisicaro, E.; Braibanti, A. Potentiometric titrations in methanol/water medium: Intertitration variabilità. Talanta 1988, 10, 769.
62. Gran, G. Determination of the equivalence point in potentiometric titrations. Part II. Analyst 1952, 77, 661.
63. Gans, P.; Sabatini, A.; Vacca, A. Investigation of equilibria in solution. Determination of equilibrium constants with the HYPERQUAD suite of programs. Talanta 1996, 43, 1739.